Background: Chronic obstructive pulmonary disease (COPD) is associated with risk
Essentials
• Whether respiratory symptoms and oxygen saturation (SpO 2 ) affect the risk of venous thromboembolism (VTE) is not known.
• We explored the association in a cohort of 8686 participants followed for a median of 9.1 years.
• Lowered SpO 2 and severe respiratory symptoms were associated with increased VTE risk.
• Chronic obstructive pulmonary disease combined with respiratory impairments had an additive effect on VTE risk.
| INTRODUCTION
The global prevalence of chronic obstructive pulmonary disease (COPD) has increased substantially during the past decades 1 and represents a major challenge to health care systems.
COPD is associated with frequent hospitalizations, grave comorbidities, and a high mortality rate. 2, 3 Around 5%-10% of patients hospitalized for acute COPD exacerbation die during the hospital stay, and 20% die during the first year after hospital discharge. 4, 5 Results from registry-based studies have reported that COPD is associated with a 2-to 5-fold increased risk of venous thromboembolism (VTE), [6] [7] [8] and the prevalence of acute pulmonary embolism (PE) is high (15%-30%) in patients with COPD hospitalized with suspected acute exacerbation. 7, 9, 10 Recent population-based cohorts, with respiratory function assessed by spirometry and validated evaluation of confounding factors and VTE events, confirmed that COPD was associated with a moderately increased risk of VTE 11 and showed that the VTE risk increased with the severity of COPD. 11, 12 Furthermore, respiratory symptoms (eg, cough, phlegm, and dyspnea) were associated with VTE risk, even in subjects with normal spirometry measurements, 11 suggesting that respiratory symptoms may represent risk markers for VTE.
Although the mechanism by which COPD causes VTE remains unknown, COPD-related complications such as lower respiratory tract infections, repeated hospitalizations, and immobilization are potential mediators. Moreover, impaired lung function and hypoxemia may result in pulmonary hypertension and systemic inflammation, which contribute to increase the risk. 13, 14 Patients with COPD with hypoxemia have been shown to have a larger mean platelet volume 15 and increased platelet aggregation 16 compared with those with normal oxygen saturation. In addition, COPD patients had higher coagulation activation than age-and sex-matched controls 17, 18 and exposure to short-term hypoxia further augmented coagulation activation. 19 Severe hypoxia was also shown to increase the incidence and size of thrombi in the inferior vena cava stenosis model in mice. 20 To the best of our knowledge, no study has investigated the association between oxygen saturation and future risk of VTE. The aims of the present study were to investigate whether measures of respiratory impairments, such as respiratory symptoms and oxygen saturation (SpO 2 ), individually and combined with COPD, were associated with increased risk of VTE. A detailed description of study participation in the Tromsø study has been published elsewhere. 21 Overall, 9577 unique individuals aged 32 to 89 years participated in ≥1 of the surveys. All subjects gave their written consent to participate, and the study was approved by the regional committee of medical and health research ethics. We excluded subjects who had officially moved out of Tromsø before the date of study enrollment (n = 7), subjects with VTE before baseline (n = 111), and subjects with missing values for SpO 2 (n = 773). Consequently, 8686 subjects were included in the study and were followed from the date of inclusion until the end of follow-up (December 31, 2016).
| METHODS

| Study population
Of these, 2752 participated in both surveys, while 2328 participated only in Tromsø 5 and 3606 participated only in Tromsø 6.
| Measurement of peripheral capillary SpO 2
SpO 2 values were measured at baseline with a digital handheld pulse oximeter (Onyx II, model 9550, Nonin Medical, Inc, Plymouth, MN, USA). The participants rested at least 15 minutes before the measurement, and the best of 3 measurements were recorded.
| Respiratory symptoms
At baseline, the participants completed a questionnaire with questions about respiratory symptoms, including presence of dyspnea in various situations, daily cough for periods of the year, chronic cough (ie, cough with continuous duration of more than 3 months during the past 2 years), and productive cough (ie, phlegm) for periods of the year.
Dyspnea was categorized into "none," "dypsnea when walking calmly or flat or when washing and dressing," and "dyspnea at rest." Cough was categorized into "none," "daily cough for periods of the year," and "chronic cough for periods of the year" (ie, periods of daily cough lasting continuously for more than 3 months in the past 2 years). Phlegm was categorized as "none" and "productive cough for periods of the year."
| Chronic obstructive pulmonary disease
Spirometry was assessed at enrollment in the Tromsø study, as previously described in detail. 12 The American Thoracic Society's criteria for spirometry testing were followed. 22 Current drug therapy was not interrupted before the test, and reversibility testing was not performed. 
| Other measurements
Height and weight were measured at enrollment in the Tromsø study, with subjects wearing light clothes and no shoes, and body mass index (BMI) was calculated (kg/m 2 ). Information on smoking status (current, former, never) and history of cardiovascular disease (CVD; ie, myocardial infarction, stroke, or angina pectoris), was collected from a self-administered questionnaire.
| Venous thromboembolism
All incident VTE events during follow-up were identified by searching the hospital discharge diagnosis registry, the autopsy registry, and the radiology procedure registry at the University Hospital of North Norway as previously described. 29 VTE events were adjudicated by thorough review of medical records, and the adjudication criteria included clinical signs and symptoms of deep vein thrombosis or PE combined with objective confirmation tests (imaging or autopsy), which resulted in a VTE diagnosis that required treatment.
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Information on date of death was obtained from the National Population Registry of Norway. were censored at the date of migration or death.
| Statistical analysis
SpO 2 was categorized into 3 categories based on the following cutoffs: ≤96%; 97%, and ≥98% based on the ≤20th percentile, 20th to 60th percentile, and 60th to 100th percentile. Incidence rates (IRs)
of VTE with 95% confidence intervals (CIs) were calculated and expressed as the number of events per 1000 person-years. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) of VTE with 95% CIs according to the different exposures (ie, oxygen saturation and respiratory symptoms). Age was used as the time scale in the Cox model, as the risk of VTE is strongly related to age. Model 1 was adjusted for sex, and Model 2 was adjusted for sex, BMI, history of CVD, and history of cancer at baseline. We additionally performed analyses stratified by COPD status (airflow without obstruction and COPD stage I-IV). The proportional hazards assumption was evaluated using Schoenfeld residuals, and no violation was found.
| RESULTS
During a median follow-up of 9.1 years, 330 participants developed an incident VTE (overall IR, 3.5; 95% CI, 2.3-3.2). Baseline characteristics according to categories of SpO 2 are shown in Table 1 . The mean age, the mean BMI levels, and the proportion of men increased over decreasing levels of SpO 2 . As expected, the proportion of subjects with COPD and respiratory symptoms increased over decreasing levels of SpO 2 ( Table 1 ). was associated with VTE only in subjects with concomitant COPD (Table 3) .
| DISCUSSION
In the present study, we investigated how individual respiratory symptoms (ie, dyspnea, cough, and phlegm) and oxygen saturation, alone and in combination with COPD, affected the VTE risk. We found that subjects with SpO 2 ≤96% (lowest 20th percentile) had a 1. 40 but not all studies. 41 Third, systemic hypoxia has been shown to accelerate thromboembolic events in mice through induction of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing 3 inflammasome complex. 42 Fourth, severe hypoxia is also reported to increase the incidence and size of thrombi in the inferior vena cava stenosis model in mice.
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In coherence with previous cohort studies, 11, 12 COPD was found to be associated with a moderately higher risk of VTE that increased with the severity of COPD. In the present study, we ad- Previously, Kubota et al 11 reported that the presence of any respiratory symptom (dyspnea, cough, and phlegm) was associated with 1.4-fold higher VTE risk in subjects with normal spirometry compared to those without respiratory symptoms. In the present study, we extended the knowledge by showing that all respiratory symptoms (dyspnea, cough, and phlegm) were individually associated with VTE risk, and that the VTE risk increased with the severity of the dyspnea and cough. Even though the mechanism for the association between respiratory symptoms and VTE risk is unknown, it is obvious that these respiratory symptoms merely are markers rather than mediators of the VTE risk. It could be speculated that the VTE risk by respiratory symptoms is attributed to associated comorbidities, such as immobility, cancer, heart failure, and others. The risk estimates for VTE by respiratory symptoms, however, remained unchanged after adjustments for BMI, cancer, and CVD.
However, we cannot rule out the possibility of residual confounding, in particular by heart failure, as we only adjusted for CVD in general. Recruitment of participants from a general population, longterm follow-up with repeated measurements of exposure and confounders, temporal sequence between exposure and outcome, and thorough adjudication of outcomes are major strengths of our study.
Objective methods were used to assess COPD and SpO 2 , as spirometry was used for measurement of airflow patterns, and SpO 2 was measured by a digital handheld pulse oximeter. The personnel who performed outcome adjudication were blinded to the baseline variable, and potential exposure misclassification would likely be nondifferential (ie, not related to the outcome). The study also had some limitations. Unfortunately, the statistical power was too low to perform subgroup analyses. For some estimates, the CIs were wide, and our findings should therefore be interpreted with caution. Moreover, participants with asthma could potentially have been misclassified as having COPD, as spirometry was performed without reversibility testing. Presence of respiratory symptoms was registered on a self-administered questionnaire and this could lead to nondifferential misclassification, which could bias our estimates toward null.
In conclusion, lowered SpO 2 and individual respiratory symptoms (dyspnea, cough, and phlegm) were associated with an increased risk of VTE. COPD combined with severe respiratory symptoms or lowered SpO 2 had an additive effect on the VTE risk. Our findings may suggest that particular attention with regard to VTE preventive strategies should be considered for patients with COPD with severe respiratory symptoms or lowered SpO 2 .
RELATIONSHIP DISCLOSURE
The authors report nothing to disclose. 
AUTHOR CONTRIBUTIONS
